Use App
New
Connect your Agent
Trending
News
Earnings
All
DIA
0.47%
SPY
0.26%
QQQ
0.02%
Trending
TSLA
5.06%
VKTX
1.93%
JEPQ
1.00%
HUT
3.63%
SKR
26.11%
DJT
1.40%
CCL
3.07%
KRMN
8.91%
RBLX
7.27%
PANW
3.21%
Feed
News
Sentiment
Earnings
Fundamentals
Info
home
Symbol
VCYT
news
Exchange:
NASDAQ
·
Updated 07:39 PM EDT
News
all
press releases
GE HealthCare Unveils Next-Gen Vivid Cardiac Ultrasound Systems
GEHC expands its Vivid cardiovascular ultrasound portfolio with three systems featuring AI tools and cSound imaging for varied care settings.
Zacks
Share to Feed
More News
Neogen Surges 102.8% in a Year: What's Driving the Rally?
NEOG shares gain 102.8% in a year as R&D investments, Food Safety growth and improving Animal Safety conditions fuel momentum despite key risks.
Zacks
Natera & Angiex Partner to Evaluate AGX101 Response With Signatera
NTRA teams with Angiex to use Signatera in a Phase 1 AGX101 trial, aiming to track ctDNA and deepen insights into treatment response.
Zacks
Should You Add Illumina Stock to Your Portfolio Now?
ILMN's sequencing growth, oncology momentum and multiomics expansion support its outlook, though cost volatility may pressure margins.
Zacks
Should You Add Teleflex Stock to Your Portfolio Now?
TFX's Vascular growth, Interventional expansion and improved leverage support its outlook, while currency volatility remains a key risk.
Zacks
McKesson to Acquire Precision Medicine Group to Strengthen Services
MCK's $2.25B Precision Medicine Group deal aims to expand clinical research and commercialization services in oncology and multispecialty care.
Zacks
Is This the Right Time to Hold Medtronic Stock in Your Portfolio?
MDT's Cardiovascular gains and renal denervation growth offer upside, but tariffs and currency headwinds cloud its outlook.
Zacks
DVA & Humana Expand Value-Based Care for Kidney Disease Patients
DaVita expands its Humana partnership to earlier-stage kidney disease, bringing value-based care to over 10,000 Medicare Advantage members.
Zacks
Is it Worth Adding Veracyte Stock to Your Portfolio Now?
VCYT's Afirma and Decipher sales momentum supports growth, while competition, macro pressures and rising investments remain key concerns.
Zacks
Here's Why You Should Retain McKesson Stock in Your Portfolio for Now
MCK's specialty distribution, oncology and technology businesses are fueling growth, while drug-pricing pressure and policy shifts pose risks.
Zacks
1
2
Advertisement
|
Remove ads.
Home
Watchlist
Trending
News
Explore
Profile